Plexium harnesses a differentiated platform of proprietary technologies and approaches to establish a robust and diverse portfolio of monovalent targeted protein degrader therapeutics
Plexium is the premier, next-generation targeted protein degradation (TPD) company. We lead the way in the rational design and discovery of Monovalent Direct Degraders and Molecular Glues.
Through our comprehensive best-in-class TPD platform powered by a proprietary ultra-high throughput cell-based screening (uHTS) technology, we are pushing the boundaries of TPD — creating limitless possibilities.
At Plexium, we are bound by our shared commitment to delivering life-changing medicines to patients. Our world-class team is highly collaborative, integrated and rooted in an entrepreneurial spirit that fuels our innovation.
Partner, The Column Group
Partner, TCG X
Executive Chairman, Plexium
Managing Partner, Pivotal Bioventure Partners
Managing Director, BVF Partners L.P.
Chief Executive Officer, President, Plexium
Operating Partner, DCVC Bio
Portfolio Manager, aMoon
